Case Commentary: When susceptibility is not enough in recurrent <i>Burkholderia cenocepacia</i> infection
ABSTRACT In this issue, B. Gaglani, T. M. Andermann, C. Wate, J. Oldan, et al. (Antimicrob Agents Chemother 70:e01542-25, 2026, https://doi.org/10.1128/aac.01542-25 ) describe a recurrent Burkholderia cenocepacia infection successfully treated with cefiderocol plus sulbactam-durlobactam. Treatment decisions are often made with incomplete microbiological and pharmacological data, even as interest in mechanism-based β-lactam combination strategies continues to grow. This case supports the utility of cefiderocol plus sulbactam-durlobactam in B. cenocepacia infection and reinforces the importance of multidisciplinary approaches to better estimate the risk of treatment failure and optimize antimicrobial therapy.
Authors
- Simone Giuliano (ORCID: https://orcid.org/0000-0003-2475-8732)
- Paolo Gaibani
- Carlo Tascini (ORCID: https://orcid.org/0000-0001-9625-6024)
Institutions
- University of Verona (IT)
- University of Udine (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Azienda Sanitaria Universitaria Integrata di Trieste (IT)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-05-28
- DOI
- https://doi.org/10.1128/aac.00467-26
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00